An ever-growing array of academic and industry resources are required to rapidly translate scientific discoveries and emerging technologies toward safe and effective regenerative medicine therapies for patients. To help, the California Institute for Regenerative Medicine (CIRM) is creating a network of Industry Resource Partners (IRP) that will make its unique resources available to help accelerate … Continue reading Stem Cell Agency Expands Industry Alliance Program to Accelerate Therapies
Dr. Maria Millan
Stem Cell Agency funds clinical trial targeting scarred urethras
A urethral stricture is scarring of the tube that carries urine out of the body. If left untreated it can be intensely painful and lead to kidney stones and infections. That's why the governing Board of the California Institute for Regenerative Medicine (CIRM) is investing more than $3.8 million in a Phase 1 clinical trial … Continue reading Stem Cell Agency funds clinical trial targeting scarred urethras
A big deal for type 1 diabetes
It’s not often you get excited talking about company mergers, but a deal announced today is something worth getting excited about, particularly if you have type 1 diabetes (T1D). Today Vertex announced it was buying ViaCyte for $320 million in cash. Why is that important? Because both companies are working on developing stem cell therapies … Continue reading A big deal for type 1 diabetes
Stem Cell Agency Board Invests in 19 Discovery Research Programs Targeting Cancers, Heart Disease and Other Disorders
THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST Dr. Judy Shizuru, Stanford University While stem cell and gene therapy research has advanced dramatically in recent years, there are still many unknowns and many questions remaining about how best to use these approaches in developing therapies. That’s why the governing Board of the California Institute … Continue reading Stem Cell Agency Board Invests in 19 Discovery Research Programs Targeting Cancers, Heart Disease and Other Disorders
Stem cell agency invests in therapy using killer cells to target colorectal, breast and ovarian cancers
While there have been some encouraging advances in treating cancer in recent decades, there are still many cancers that either resist treatment or recur after treatment. Today the governing Board of the California Institute for Regenerative Medicine (CIRM) approved investing in a therapy targeting some of these hard-to-treat tumors. BioEclipse Therapeutics Inc. was awarded nearly … Continue reading Stem cell agency invests in therapy using killer cells to target colorectal, breast and ovarian cancers
Stem Cell Agency Board Approves Funding for Rare Immune Disorder
THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST Taylor Lookofsky (center), a person with IPEX syndrome, with his father Brian and Dr. Rosa Bacchetta IPEX syndrome is a rare condition where the body can’t control or restrain an immune response, so the person’s immune cells attack their own healthy tissue. The syndrome mostly affects … Continue reading Stem Cell Agency Board Approves Funding for Rare Immune Disorder
Lack of diversity leaves cloud hanging over asthma drug study
Asthma spacer, photo courtesy Wiki Media Creative Commons THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST If you want to know if a new drug or therapy is going to work in the people it affects the most you need to test the drug or therapy in the people most affected by the disease. … Continue reading Lack of diversity leaves cloud hanging over asthma drug study
Some good news for people with dodgy knees
THIS BLOG IS ALSO AVAILABLE AS AN AUDIOCAST Graphic contrasting a healthy knee with one that has osteoarthritis About 10% of Americans suffer from knee osteoarthritis, a painful condition that can really impair mobility and quality of life. It's often caused by an injury to cartilage, say when you were playing sports in high school … Continue reading Some good news for people with dodgy knees
CIRM funds clinical trials targeting heart disease, stroke and childhood brain tumors
Gary Steinberg (Jonathan Sprague) Heart disease and stroke are two of the leading causes of death and disability and for people who have experienced either their treatment options are very limited. Current therapies focus on dealing with the immediate impact of the attack, but there is nothing to deal with the longer-term impact. The CIRM … Continue reading CIRM funds clinical trials targeting heart disease, stroke and childhood brain tumors
Medeor Therapeutics Completes Enrollment in CIRM-Funded Clinical Trial for Kidney Transplant Patients
A CIRM-funded clinical trial to help kidney transplant patients avoid the need for anti-rejection or immunosuppressive medications has completed enrollment and transplantation of all patients. Medeor Therapeutics’ MDR-101 Phase 3 multi-center clinical trial involved 30 patients; 20 of them were treated with MDR-101, and 10 control subjects were given standard care. CIRM awarded Medeor, based … Continue reading Medeor Therapeutics Completes Enrollment in CIRM-Funded Clinical Trial for Kidney Transplant Patients
The Stem Cellar 